Fetal MRI Scoring System Quantifies Severity in Trisomy 13, 18, and CHARGE

The clinical management of fetuses with trisomy 13 and trisomy 18 is increasingly complex as the historical assumption of universal lethality is challenged by reports of prolonged survival. While cell-free DNA (genetic material from the placenta found in maternal blood) and ultrasound remain primary screening tools, identifying specific phenotypic variations that dictate postnatal prognosis is difficult [1, 2]. Fetal magnetic resonance imaging (MRI) is frequently used to characterize central nervous system anomalies, such as defects of the corpus callosum (the primary white matter bridge between brain hemispheres), which were identified in 124 fetuses in a recent cohort where genetic testing confirmed trisomy 18 and 13 [3]. In cases of ventriculomegaly (enlargement of the brain's fluid-filled cavities), the risk of detecting an associated abnormality on MRI is significantly higher in moderate cases (13 to 15 mm) compared to mild cases (10 to 12 mm), with an odds ratio of 8.1 (95% CI, 2.3 to 29.0; p = 0.001) [4]. Precise risk stratification is vital because even in apparently isolated mild ventriculomegaly, the prevalence of neurodevelopmental delay is 7.9% (95% CI, 4.7 to 11.1%), and the false-negative rate for associated anomalies on prenatal imaging reaches 7.4% [5]. As care becomes more individualized, standardized tools are needed to quantify in utero disease severity and guide clinical decision-making.